MoonLake Immunotherapeutics (MLTX) Payables (2020 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Payables of $23.4 million for Q1 2026, up 94.74% year-over-year from $12.0 million in Q1 2025, and down 20.89% quarter-over-quarter from $29.6 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Payables (2020 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Payables history runs 7 years deep, the most recent figure standing at $23.4 million for Q1 2026.
- In Q1 2026, Payables rose 94.74% year-over-year to $23.4 million; the TTM figure through Mar 2026 stood at $23.4 million (up 94.74% YoY), while the FY2025 annual figure was $29.6 million, up 228.66% from the prior year.
- Payables for Q1 2026 stood at $23.4 million, down from $29.6 million in the prior quarter.
- The five-year high for Payables was $29.6 million in Q4 2025, with the low at $150000.0 in Q1 2022.
- The 5-year median for Payables is $4.4 million (2023), against an average of $8.9 million.
- The sharpest annual moves came in 2022 and 2023: Payables sank 98.46% in 2022, then surged 2451.6% in 2023.
- MoonLake Immunotherapeutics' Payables stood at $254972.0 in 2022, then surged by 620.74% to $1.8 million in 2023, then jumped by 389.31% to $9.0 million in 2024, then jumped by 228.66% to $29.6 million in 2025, then slipped by 20.89% to $23.4 million in 2026.
- Business Quant data shows MLTX's Payables at $23.4 million in Q1 2026, $29.6 million in Q4 2025, and $25.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | 17.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.04 Mn |
| Mar 31, 2026 | 23.38 Mn |
| Dec 31, 2025 | 29.55 Mn |
| Sep 30, 2025 | 25.28 Mn |
| Jun 30, 2025 | 17.08 Mn |
| Mar 31, 2025 | 12.01 Mn |
| Dec 31, 2024 | 8.99 Mn |
| Sep 30, 2024 | 10.71 Mn |
| Jun 30, 2024 | 5.14 Mn |
| Mar 31, 2024 | 3.48 Mn |
| Dec 31, 2023 | 1.84 Mn |
| Sep 30, 2023 | 3.40 Mn |
| Jun 30, 2023 | 4.36 Mn |
| Mar 31, 2023 | 3.83 Mn |
| Dec 31, 2022 | 254,972.00 |
| Sep 30, 2022 | 1.06 Mn |
| Jun 30, 2022 | 791,061.00 |
| Mar 31, 2022 | 150,000.00 |
| Dec 31, 2021 | 16.57 Mn |
| Dec 31, 2020 | 78,063.00 |